CA3137869A1 - Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions - Google Patents

Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions Download PDF

Info

Publication number
CA3137869A1
CA3137869A1 CA3137869A CA3137869A CA3137869A1 CA 3137869 A1 CA3137869 A1 CA 3137869A1 CA 3137869 A CA3137869 A CA 3137869A CA 3137869 A CA3137869 A CA 3137869A CA 3137869 A1 CA3137869 A1 CA 3137869A1
Authority
CA
Canada
Prior art keywords
mhz
nmr
mmol
cdc13
ppm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3137869A
Other languages
English (en)
French (fr)
Inventor
Gregory Cuny
Alexei Degterev
Sameer NIKHAR
Siddharth Balachandran
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute for Cancer Research
Tufts University
University of Houston System
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3137869A1 publication Critical patent/CA3137869A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3137869A 2019-05-16 2020-05-14 Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions Pending CA3137869A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962848648P 2019-05-16 2019-05-16
US201962848719P 2019-05-16 2019-05-16
US62/848,648 2019-05-16
US62/848,719 2019-05-16
PCT/US2020/032784 WO2020232190A1 (en) 2019-05-16 2020-05-14 Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions

Publications (1)

Publication Number Publication Date
CA3137869A1 true CA3137869A1 (en) 2020-11-19

Family

ID=70919255

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3137869A Pending CA3137869A1 (en) 2019-05-16 2020-05-14 Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions

Country Status (6)

Country Link
US (1) US12516055B2 (https=)
EP (2) EP4480485A3 (https=)
JP (2) JP7546603B2 (https=)
AU (1) AU2020275304B2 (https=)
CA (1) CA3137869A1 (https=)
WO (1) WO2020232190A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11174255B2 (en) * 2017-05-15 2021-11-16 University Of Houston System Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases
EP4480485A3 (en) * 2019-05-16 2025-02-26 University of Houston System Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions
CN113072471B (zh) * 2021-03-02 2022-09-16 四川美大康华康药业有限公司 一种利非司特中间体及其制备方法
WO2024097805A1 (en) * 2022-11-01 2024-05-10 Trustees Of Tufts College Mixed lineage kinase domain like pseudokinase (mlkl) activators
WO2024199388A1 (zh) * 2023-03-29 2024-10-03 微境生物医药科技(上海)有限公司 作为myt1抑制剂的化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US6150359A (en) * 1997-08-20 2000-11-21 Warner-Lambert Company Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
KR20020070520A (ko) 2000-01-27 2002-09-09 워너-램버트 캄파니 신경퇴행성 질병의 치료를 위한 피리도피리미디논 유도체
WO2014031571A1 (en) * 2012-08-21 2014-02-27 Icahn School Of Medicine At Mount Sinai Treatment of viral infections
WO2015179436A1 (en) 2014-05-19 2015-11-26 Sanford-Burnham Medical Research Institute Inflammation therapy using mekk3 inhibitors or blocking peptides
US11174255B2 (en) 2017-05-15 2021-11-16 University Of Houston System Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases
EP4480485A3 (en) * 2019-05-16 2025-02-26 University of Houston System Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions

Also Published As

Publication number Publication date
EP4480485A3 (en) 2025-02-26
US20220194937A1 (en) 2022-06-23
US12516055B2 (en) 2026-01-06
AU2020275304B2 (en) 2025-01-23
AU2020275304A1 (en) 2021-12-16
JP2022533182A (ja) 2022-07-21
WO2020232190A1 (en) 2020-11-19
JP7546603B2 (ja) 2024-09-06
EP3968991B1 (en) 2024-07-31
EP3968991A1 (en) 2022-03-23
EP3968991C0 (en) 2024-07-31
JP2024170457A (ja) 2024-12-10
EP4480485A2 (en) 2024-12-25

Similar Documents

Publication Publication Date Title
AU2020275304B2 (en) Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions
CN114555588B (zh) 作为axl抑制剂的喹唑啉类化合物
JP6759514B2 (ja) ブロモドメインに対して活性な化合物
AU2017268536B2 (en) Novel compounds and compositions for inhibition of FASN
TWI222971B (en) Antagonists of MCP-1 function and methods of use thereof
KR101530117B1 (ko) 야누스 키나제 억제제 화합물 및 방법
JP2021152064A (ja) 乳酸脱水素酵素の小分子阻害剤及びその使用方法
CN108794411B (zh) 某些化学实体、组合物及方法
JP2023512038A (ja) 化合物及びその使用
AU2018300123B2 (en) New heteroaryl amide derivatives as selective inhibitors of histone deacetylases 1 and 2 (HDAC1-2)
US11066370B2 (en) Kinase inhibitor compounds, compositions, and methods of treating cancer
WO2016026445A1 (zh) 作为fgfr激酶抑制剂的吲唑类化合物及其制备和应用
CN107709320A (zh) 一种吡啶并氮杂环化合物及其制备方法和用途
US20240327403A1 (en) PYRIDO[2,3-d]PYRIMIDIN-7-ONES AND RELATED COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
WO2014079232A1 (zh) 7-氧代吡啶并嘧啶类化合物及其药用组合物和应用
KR20170045308A (ko) 인간 면역결핍 바이러스 복제의 억제제로서 이미다조[1,2-a]피리딘 유도체
CN106795152B (zh) 蛋白激酶抑制剂
CN106986832A (zh) Vegfr3抑制剂
CN114981256B (zh) 干扰素基因刺激物sting的单环激动剂
CN115003383B (zh) 干扰素基因刺激物sting的双环激动剂
CN118302413A (zh) 抗SARS-CoV-2药
KR102288434B1 (ko) 신규한 (이소프로필-트리아졸릴)피리디닐 치환된 벤조옥사지논 또는 벤조티아지논 유도체 및 이의 용도
Meng et al. Design, synthesis and dipeptidyl peptidase 4 inhibition of novel aminomethyl biaryl derivatives
Zangi Synthesis of Novel Antiparasitic Pyrazolopyrimidines and Antiviral N-Hydroxypyridones and N-Hydroxynaphthyridinones
CN101228120A (zh) Hiv逆转录酶抑制剂

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240501

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250509

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250509

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20250530

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250626

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251024

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251215

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251215

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251215